[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"West Virginia University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":607},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,27,0,25,[9,44,66,95,124,151,175,197,219,239,266,289,310,329,350,373,395,423,444,469,495,515,538,563,586],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100644841","cardiometabolic-impact-of-a-produce-prescription-program-in-patients-with-type-2-diabetes-and-food-insecurity-100644841",false,"NCT07674979","Cardiometabolic Impact of a Produce Prescription Program in Patients With Type 2 Diabetes and Food Insecurity","A Randomized Crossover Trial Evaluating the Cardiometabolic Impact of a Produce Prescription Program in Patients With Type 2 Diabetes and Food Insecurity","GARDEN-CARDIO","Inclusion Criteria:\n\n* Diagnosis of type 2 diabetes mellitus\n* Most recent HbA1c \\>8% within the prior 6 months\n* Must have had a clinic visit within the past 6 months\n* Positive screening for food insecurity based on the USDA 6-item food security survey\n* Receiving care through WVU cardiometabolic, endocrinology, or primary care clinics\n* Able and willing to provide written informed consent\n\nExclusion Criteria:\n\n* End-stage renal disease\n* Advanced heart failure\n* Severe cognitive impairment\n* Chronic pancreatitis\n* Pancreatic malignancy\n* Pregnancy at time of enrollment\n* Anticipated inability to utilize intervention vouchers (e.g., lack of access to Walmart)","ALL","18 Years",{"count":21,"type":22},88,"ESTIMATED","INTERVENTIONAL",[25],"NA","This study is testing whether providing monthly vouchers to buy fruits and vegetables can help improve blood sugar control in adults with type 2 diabetes. People receiving care at WVU clinics who recently had an HbA1c level above 8% will be invited to participate in the study. Those who are interested will speak with a study coordinator, be screened for eligibility, and, if eligible, will provide written consent to join the study. Participants will be randomly assigned to one of two groups. One group will receive $100 per month in produce-only grocery vouchers and standardized dietary education for 5 months, followed by 5 months of usual diabetes care. The second group will receive usual diabetes care first for 5 months, followed by 5 months of produce-only grocery vouchers and standardized dietary education. This crossover design allows all participants to experience both approaches during the study. Researchers will measure changes in blood sugar (HbA1c) as the main outcome. Other outcomes include blood pressure, cholesterol levels, body weight, diet quality, food security, anxiety symptoms, depressive symptoms, and physical activity. These will be assessed through lab tests, clinic measurements, and surveys at certain time points during the 10 month study period. The study team will also track how often participants use the vouchers and any challenges they face. The risks of participating are expected to be minimal and similar to routine diabetes care. The total study duration, including enrollment, participation, and analysis, is expected to be about 18 months.",[28],"Type 2 Diabetes",[30],"Food Insecurity","NOT_YET_RECRUITING","2026-06-24",{"date":34,"type":35},"2026-06-30","ACTUAL",{"date":37,"type":22},"2026-07",{"date":39,"type":22},"2027-06",{"name":41,"class":42},"West Virginia University","OTHER",1,{"id":45,"slug":46,"hasResults":12,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":23,"phases":53,"briefSummary":54,"conditions":55,"keywords":57,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":63,"leadSponsor":65,"locationsCount":43},"100644408","trans-auricular-vagal-nerve-stimulation-in-patients-with-ibs-c-100644408","NCT07662083","Trans Auricular Vagal Nerve Stimulation in Patients With IBS-C","Randomized Controlled Trial Evaluating Trans Auricular Vagal Nerve Stimulation in Patients With Irritable Bowel Syndrome Constipation Subtype","Inclusion Criteria:\n\n* Referred to the WVU Department of Gastroenterology and Hepatology\n* Diagnosis of IBS-C\n\nExclusion Criteria:\n\n* Failure of second-line therapy with secretagogues (linaclotide, lubiprostone, plecanatide, or tenapanor)\n* Failure of third-line therapy with tegaserod\n* Known debilitating psychiatric illness\n* Cognitive impairment\n* Pregnancy\n* Prisoners\n* Active substance use disorder\n* Concurrent opioid use\n* History of major gastrointestinal surgery resulting in luminal alteration\n* History of vagotomy\n* Secondary causes of constipation (e.g., opioid use, uncontrolled hypothyroidism, celiac disease)",{"count":52,"type":22},80,[25],"This study evaluates the efficacy and safety of transcutaneous auricular vagus nerve stimulation (ta-VNS) in adults with constipation-predominant irritable bowel syndrome (IBS-C). Participants will be randomized to receive either active or sham stimulation using a non-invasive auricular device over a 60-day period.\n\nThe primary objectives are to assess changes in symptom severity and quality of life using validated instruments, including the IBS Symptom Severity Scale (IBS-SSS) and the IBS Quality of Life questionnaire (IBS-QOL). Secondary assessments include safety and participant compliance.\n\nThis study aims to determine whether ta-VNS is an effective non-invasive therapeutic modality for improving symptoms and quality of life in patients with IBS-C.",[56],"Irritable Bowel Syndrome (IBS-C)",[58],"Trans Auricular Vagal Nerve Stimulation","2026-06-17",{"date":61,"type":35},"2026-06-23",{"date":37,"type":22},{"date":64,"type":22},"2027-07",{"name":41,"class":42},{"id":67,"slug":68,"hasResults":12,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":4,"eligibilityCriteria":72,"healthyVolunteers":12,"sex":18,"minAge":73,"maxAge":19,"enrollmentInfo":74,"targetDuration":4,"studyType":23,"phases":76,"briefSummary":77,"conditions":78,"keywords":82,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":43},"100559457","tailored-mgso4-supplementation-to-reduce-complications-in-pediatric-heart-surgery-100559457","NCT06564376","Tailored MgSO4 Supplementation to Reduce Complications in Pediatric Heart Surgery","Individually Tailored MgSo4 Supplementation to Reduce Cardiac and Renal Complications in Pediatric Heart Surgery","Inclusion Criteria:\n\n* Children undergoing cardiac surgery utilizing cardiopulmonary bypass\n\nExclusion Criteria:\n\n* Children undergoing cardiac surgery without cardiopulmonary bypass\n* Children with Renal disease\n* Children with pre-existing arrhythmia\n* Children on anti-arrhythmia medication","0 Years",{"count":75,"type":22},96,[25],"Lay Summary\n\nThis study tests two ways of measuring blood magnesium after heart surgery. Children who need heart surgery may have heart and kidney problems after surgery. The right amount of magnesium in blood reduces this risk. This study will test the best way to measure magnesium. This will let doctors choose the right dose of MgSO4. MgSO4 is a magnesium supplement. Taking MgSO4 after heart surgery helps children. For each child, it is best to personalize MgSO4 dose. This is based on the amount of magnesium in blood. This study will test two ways of personalizing MgSO4 dose.\n\nIn the blood, there are two kinds of magnesium. Usually, blood magnesium tests measure both forms together. This does not say anything about active magnesium. This study will measure the two forms separately. Then, MgSO4 will be given based on either the active or whole magnesium. Measuring active magnesium is good. Active magnesium levels change faster than total. That means active magnesium tests may better protect children. Also, active magnesium has more of an impact on heart and kidney function. Focusing on the active form will help these organs stay healthy.\n\nTo test how well the MgSO4 is working, heart and kidneys will be examined. After surgery, certain harmful heart rhythms can occur. The types and number of harmful rhythms will be studied. Kidney problems can also happen after heart surgery. Kidney health will be studied. To help understand how active magnesium works, further tests will be done. These tests will look for evidence of poor health in the cells that make up the heart, kidney, and blood.",[79,80,81],"AKI - Acute Kidney Injury","Arrythmia","Congenital Heart Disease",[83,84,85,86],"Acute Kidney Injury","Arrhythmias","Congenital heart surgery","Cardiopulmonary bypass","2026-06-12",{"date":89,"type":35},"2026-06-16",{"date":91,"type":22},"2026-08-01",{"date":93,"type":22},"2029-06",{"name":41,"class":42},{"id":96,"slug":97,"hasResults":12,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":4,"eligibilityCriteria":101,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":102,"targetDuration":4,"studyType":23,"phases":104,"briefSummary":105,"conditions":106,"keywords":108,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":120,"completionDateStruct":121,"leadSponsor":123,"locationsCount":4},"100643057","pilot-study-of-intermittent-fasting-with-immune-checkpoint-inhibitors-100643057","NCT07645742","Pilot Study of Intermittent Fasting With Immune Checkpoint Inhibitors","Feasibility and Immunometabolic Effects of Intermittent Fasting During Immune Checkpoint Inhibitor Therapy: A Randomized Pilot Study in Advanced Solid Tumors","Inclusion Criteria:\n\n* Diagnosis of advanced esophageal, gastric, non-small cell lung cancer (NSCLC), HCC, cholangiocarcinoma, melanoma, RCC, or MSI-H cancer\n\n  * Planned treatment with ICI-based therapy\n  * ECOG 0-2\n  * Ability to provide informed consent\n  * Willingness to follow dietary guidance and record adherence\n  * BMI = 23-40\n\nExclusion Criteria:\n\n* Diabetes requiring insulin\n\n  * Active eating disorders\n  * Sarcopenia and\u002For cachexia (mild, moderate, severe), including sarcopenic obesity\n  * A history of hypoglycemia, including idiopathic and postbariatric hypoglycemia\n  * Patients taking sulfonylureas (concern for hypoglycemia with fasting)\n  * Night shift workers (at discretion of investigator)\n  * \\>10% weight loss within the past 3 months through self-reporting or chart review.\n  * Any uncontrolled autoimmune condition or recent high-dose steroid use\n  * Severe GI or endocrine disorders precluding fasting including but not limited to malabsorption syndromes, gastroparesis, or Addison's\u002FCushing's\n  * Pregnant or breastfeeding",{"count":103,"type":22},90,[25],"This single-site, randomized pilot study will evaluate whether intermittent fasting is feasible and safe for patients with advanced solid tumors who are starting immune checkpoint inhibitor (ICI) therapy at the WVU Cancer Institute. Participants will be assigned to 1 of 3 groups: usual care with no fasting, alternate-day fasting (ADF), or time-restricted eating (TRE).\n\nParticipants in the ADF group will follow cycles of 12 hours of eating followed by 36 hours of fasting every other day. Participants in the TRE group will eat all daily calories within an 8-hour window each day. The fasting intervention will begin within 1 week of starting ICI treatment and continue for approximately 20-24 weeks during 8 cycles of therapy.\n\nThe study will evaluate adherence to the fasting regimens and compare side effects between groups. Researchers will also study changes in metabolic and immune biomarkers, fatigue, sleep, and quality of life. Participants will be followed for 30 days after completion of the intervention to monitor safety and tolerability.",[107],"Cancer (Advanced Stage)",[109,110,111,112,113,114,115,116,117],"esophogeal","gastric","lung","cholangiocarcinoma","melanoma","Hepatocellular Carcinoma","Immune Checkpoint Inhibitor","Microsatellite Instability-High","Renal Cell Carcinoma","2026-06-08",{"date":87,"type":35},{"date":37,"type":22},{"date":122,"type":22},"2029-02",{"name":41,"class":42},{"id":125,"slug":126,"hasResults":12,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":4,"eligibilityCriteria":130,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":131,"targetDuration":133,"studyType":134,"phases":4,"briefSummary":135,"conditions":136,"keywords":4,"overallStatus":142,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":43},"100640536","eus-guided-ablation-rfa-and-mwa-for-pancreatic-and-other-gastrointestinal-lesions-registry-100640536","NCT07625189","EUS-Guided Ablation (RFA and MWA) for Pancreatic and Other Gastrointestinal Lesions Registry","Prospective Observational Registry of EUS-Guided Ablation (RFA and MWA) for Pancreatic and Other Gastrointestinal Lesions","Inclusion Criteria:\n\n* Adults ≥ 18 years of age.\n* Diagnosis of a pancreatic premalignant lesion or malignancy, and other gastrointestinal or hepatobiliary lesion for which EUS-guided ablation is planned as part of standard clinical care.\n* At least one clinically identified target lesion for which RFA or MWA is performed.\n\nExclusion Criteria:\n\n* In the judgment of the treating clinician, inclusion in the registry would not be appropriate\n* The individual is expected to be unable to complete routine clinical follow-up.",{"count":132,"type":22},50,"1 Year","OBSERVATIONAL","This is a single-center, investigator-initiated, prospective observational registry that will collect longitudinal clinical data on adult patients (≥18 years) undergoing endoscopic ultrasound (EUS)-guided radiofrequency ablation (RFA) or microwave ablation (MWA) for pancreatic and other gastrointestinal\u002Fhepatobiliary lesions as part of routine clinical care. The registry will not alter standard-of-care management. Data will be abstracted from the medical record and routine clinical systems. Primary outcomes include change in target lesion size on clinically obtained imaging and overall survival following ablation. Secondary outcomes include changes in tumor biomarkers, adverse events, non-target lesion changes, and patient-reported symptoms.",[137,138,139,140,141],"RFA","Microwave Ablation","Pancreatic Lesion","Gastrointestinal Lesions","Ablation Techniques","RECRUITING","2026-05-30",{"date":145,"type":35},"2026-06-04",{"date":147,"type":35},"2026-03-10",{"date":149,"type":22},"2028-03",{"name":41,"class":42},{"id":152,"slug":153,"hasResults":12,"nctId":154,"briefTitle":155,"officialTitle":156,"acronym":4,"eligibilityCriteria":157,"healthyVolunteers":158,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":159,"targetDuration":4,"studyType":23,"phases":161,"briefSummary":164,"conditions":165,"keywords":4,"overallStatus":142,"whyStopped":4,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":168,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":174,"locationsCount":43},"100579120","phase-1-lipomas-treated-with-subcutaneous-injections-of-cooled-or-warmed-sodium-chloride-100579120","NCT06820164","Lipomas Treated With Subcutaneous Injections of Cooled or Warmed Sodium Chloride","Lipomas Treated With Subcutaneous Injections of Cooled or Warmed Sodium Chloride: an Exploratory Study","Inclusion Criteria:\n\n* At least one clinically diagnosed subcutaneous lipoma\n\nExclusion Criteria:\n\n* Unable to give informed consent\n* Participant has a lipoma on the face\n* Lipomas located subfascial or within deep tissue (e.g., intramuscular lipomas)\n* Lipomas larger than 10 cm in diameter (fat deposits exceeding 500 mL in volume)\n* Rapidly growing lipomas\n* Lipomas exhibiting abnormal ultrasound findings (e.g., complex hyperechoic patterns, internal heterogeneity, or multilobulated appearance)\n* Pregnant women",true,{"count":160,"type":22},20,[162,163],"PHASE1","PHASE2","Lipomas are benign tumors composed of mature adipose tissue. While harmless, these are the most common type of soft tissue growths with some patients developing numerous lipomas. Patients often seek removal for cosmesis, or symptoms caused by location and\u002For compression of surrounding structures. This exploratory study aims to evaluate the effectiveness of subcutaneous injections of cooled normal saline as a treatment option for lipomas. The study will assess whether this technique could serve as a viable alternative to existing treatment options, especially compared to topically applied fat-freezing devices. The Investigators propose that this method may offer a more comfortable nonsurgical option for targeted fat reduction, as the cold temperatures are applied directly to the lipomas.\n\nAmendment to Protocol Feb 2026- Including and additional ARM of the study to evaluate the effectiveness of subcutaneous injections of warmed normal saline as a treatment option for lipomas.",[166],"Lipoma","2026-04-23",{"date":169,"type":35},"2026-04-29",{"date":171,"type":35},"2025-05-08",{"date":173,"type":22},"2027-01",{"name":41,"class":42},{"id":176,"slug":177,"hasResults":12,"nctId":178,"briefTitle":179,"officialTitle":180,"acronym":4,"eligibilityCriteria":181,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":182,"targetDuration":4,"studyType":23,"phases":184,"briefSummary":185,"conditions":186,"keywords":188,"overallStatus":142,"whyStopped":4,"lastUpdateSubmitDate":190,"lastUpdatePostDateStruct":191,"startDateStruct":192,"completionDateStruct":194,"leadSponsor":196,"locationsCount":43},"100587061","phase-1-leflunomide-in-combination-with-decitabine-for-treatment-of-relapsed-or-refractory-myelodysplastic-syndromes-100587061","NCT06923488","Leflunomide in Combination With Decitabine for Treatment of Relapsed or Refractory Myelodysplastic Syndromes","Phase I\u002FII Study of Leflunomide in Combination With Decitabine for Treatment of Relapsed or Refractory (R\u002FR) Myelodysplastic Syndromes (MDS)","Inclusion Criteria:\n\n* Patient has pathologically confirmed diagnosis of MDS\n* Patient has currently measurable disease meeting the following criteria:\n\n  * Bone marrow biopsy with more than 5% blasts, AND\n  * Absolute neutrophil count (ANC) less than 1,000\u002FmcL, and\u002For platelet count less than 100,000\u002FmcL and\u002For hemoglobin levels less than 10g\u002FdL\n* Patient has received one prior treatment with a DNA methyltransferase inhibitor (DNMTi), also commonly called hypomethylating agent (HMA). Patients whose MDS has IDH1\u002FIDH2 mutations should have received at least one available IDH1\u002FIDH2 inhibitor\n* Patient has an Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2\n* Patient has the following required baseline laboratory data (eligibility can be based on local lab results):\n\n  * Total serum bilirubin level less than or equal to 2 times ULN\n  * Estimated glomerular filtration rate (eGFR) greater than or equal to 45 mL\u002Fmin\u002F1.73 m2\n* Patients who have undergone alloHSCT are eligible if they are more than 28 days post stem cell infusion, have no evidence of GVHD \\> Grade 1, and are more than a week off all immunosuppressive therapy\n* If a female of childbearing potential, the patient has a negative serum or urine pregnancy test result within 7 days prior to the first dose of treatment. Women of non-childbearing potential are those who are postmenopausal greater than one year or who have had a bilateral tubal ligation or hysterectomy\n* If female of childbearing potential or a male patient, patient agrees to use an effective contraceptive method from the time of informed consent, during the course of the study, and for 3 months following the last dose of treatment\n* Patient understands and voluntarily signs the written informed consent prior to any study-specific procedures. A copy of the signed informed consent form will be retained by the treating institution\n\nExclusion Criteria:\n\n* Patients receiving any other investigational agents, or concurrent chemotherapy or immunotherapy\n* Patients with progression to acute myeloid leukemia\n* Patients with other malignancies requiring systemic chemotherapy, immunotherapy or targeted therapy in the last four weeks\n* Patients with uncontrolled bacterial, viral or fungal infections (undergoing appropriate treatment and with progression of clinical symptoms)\n* Patients with active or latent tuberculosis\n* Uncontrolled intercurrent illness including, but not limited to, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\u002Fsocial situations that per Principal Investigator's judgment would limit compliance with study requirements\n* Females who are pregnant or breast feeding\n* Any other clinical conditions that in the opinion of the investigator would make the subject unsuitable for the study",{"count":183,"type":22},26,[162,163],"The goal of this interventional clinical trial is to evaluate the safety and tolerability of leflunomide in combination with decitabine as treatment for patients with relapsed or refractory myelodysplastic syndromes (R\u002FR MDS).\n\nThe main question this study aims to answer are to evaluate and estimate the maximum tolerated doses and\u002For biologically active doses of the combination of leflunomide-decitabine in participants.\n\nDecitabine will be administered at a dose of 20 mg\u002Fm2 by continuous intravenous infusion over one hour repeated daily for 5 days with repeating cycle every 4 weeks. Leflunomide is administered orally at 10 to 20 mg once daily (without a loading dose) for 14 to 21 days, as part of a 28-day treatment cycle in adult subjects with R\u002FR MDS. After 12 cycles (study duration) responding patients can continue progression with the assigned doses.",[187],"Myelodysplastic Syndromes",[189],"relapsed or refractory","2026-04-20",{"date":167,"type":35},{"date":193,"type":35},"2025-07-15",{"date":195,"type":22},"2028-10",{"name":41,"class":42},{"id":198,"slug":199,"hasResults":12,"nctId":200,"briefTitle":201,"officialTitle":202,"acronym":4,"eligibilityCriteria":203,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":204,"enrollmentInfo":205,"targetDuration":4,"studyType":23,"phases":207,"briefSummary":208,"conditions":209,"keywords":4,"overallStatus":142,"whyStopped":4,"lastUpdateSubmitDate":211,"lastUpdatePostDateStruct":212,"startDateStruct":214,"completionDateStruct":216,"leadSponsor":218,"locationsCount":43},"100623795","phase-1-actinic-keratoses-treated-with-5-fluorouracil-plus-aluminum-100623795","NCT07401277","Actinic Keratoses Treated With 5-fluorouracil Plus Aluminum","Actinic Keratoses Treated With 5-fluorouracil Plus Aluminum: an Exploratory Study","Inclusion Criteria:\n\n* Less than 50 years due to this being a pathology of adults that develops in chronically sun-damaged skin, individuals \\\u003C50 years of age are excluded from this study.\n* Patients with 4-15 clinically diagnosed AKs on the scalp (16 patients) or on the forearms (16 patients) being followed at the Mohs Surgery clinic by WVU Medicine Dermatology\n* Performance status: ECOG Performance status less than or equal to 2\n* Patient must provide informed consent\n\nExclusion Criteria:\n\n* Presence of a suspected squamous cell carcinoma (SCC) or basal cell carcinoma (BCC) lesion or open wound on the treatment site (scalp or forearm)\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to 15% ACH or other agents used in this study\n* Use of one or more of the following products within the past month:\n\n  * Tanning skin colorants\n  * Prescription topical drugs\n  * Immunomodulatory or immunosuppressive medicines\n  * Chemotherapy or cytotoxic medications\n  * Photodynamic therapy (PDT) or other treatments of pre-cancers on the skin\n  * Vitamin A derivatives taken by mouth\n* Patients receiving any other investigational agents\n* Patients with immunosuppression or weakened immune systems who may be at a higher risk of infection, including patients who have had chronic lymphocytic leukemia (CLL), who have received transplants, or who are taking medications such as chronic steroids or rheumatoid arthritis (RA) drugs","50 Years",{"count":206,"type":22},32,[162],"This study is looking at a new way to treat actinic keratoses, which are rough, scaly spots on the skin caused by long-term sun exposure. These spots are common in older adults and, if not treated, can sometimes develop into a type of skin cancer.\n\nDoctors often treat areas with many of these spots by using a prescription cream called 5-fluorouracil (5-FU), which helps remove damaged skin cells. This study is testing whether adding aluminum chloride hexahydrate, a medication commonly used to stop bleeding during skin procedures, can improve how well the cream works.\n\nPeople who take part in this study will receive one of two treatments applied to their skin:\n\nStandard treatment with 5% 5-fluorouracil cream, or A combination of 5% 5-fluorouracil cream plus 15% aluminum chloride hexahydrate cream\n\nThe treatment will be applied for one week. A dermatologist will examine the treated skin areas, count the number of actinic keratoses, and take photographs before treatment begins, shortly after treatment ends, and again about eight weeks later. These visits help researchers compare how well each treatment reduces the number of skin spots over time.\n\nThe goal of this study is to learn whether adding aluminum chloride hexahydrate to standard treatment helps reduce actinic keratoses more effectively than standard treatment alone.",[210],"Actinic Keratoses","2026-04-17",{"date":213,"type":35},"2026-04-22",{"date":215,"type":35},"2026-02-06",{"date":217,"type":22},"2027-08",{"name":41,"class":42},{"id":220,"slug":221,"hasResults":12,"nctId":222,"briefTitle":223,"officialTitle":224,"acronym":4,"eligibilityCriteria":225,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":226,"targetDuration":4,"studyType":23,"phases":227,"briefSummary":228,"conditions":229,"keywords":4,"overallStatus":142,"whyStopped":4,"lastUpdateSubmitDate":232,"lastUpdatePostDateStruct":233,"startDateStruct":234,"completionDateStruct":236,"leadSponsor":238,"locationsCount":43},"100534364","rtms-over-the-dorsolateral-prefrontal-cortex-for-the-treatment-of-impulse-control-disorders-in-parkinsons-disease-100534364","NCT06237868","rTMS Over the Dorsolateral Prefrontal Cortex for the Treatment of Impulse Control Disorders in Parkinson's Disease","The Effects of High-Frequency Repetitive Transcranial Magnetic Stimulation on Impulse Control Disorders in Parkinson's Disease Patients on Dopamine Replacement Therapy.","Inclusion Criteria:\n\n* Clinician-confirmed diagnosis of PD\n* Ability to provide informed consent, written and verbal\n* Clinician-diagnosed impulse control disorder or impulse control behaviors including punding\u002Fhobbyism and dopamine dysregulation syndrome\n* A Beck Depression Inventory (BDI) (Beck et al., 1961) score of 14 or lower\n* A Montreal Cognitive Assessment (MoCA) (Nasreddine et al., 2005) score of 20 or higher\n* On dopamine-replacement therapy\n\nExclusion Criteria:\n\n* History of seizures or epilepsy\n* History of brain lesions (such as multiple sclerosis, tumor) reported\n* History of vascular issues in the brain, such as stroke\n* History of a moderate to severe traumatic brain injury\n* Meeting the criteria for a major psychiatric illness such as schizophrenia or depression (BDI score of 14 or higher).\n* Having significant cognitive impairment (assessed by MoCA, cutoff score of 20) (Nasreddine, et al., 2005)\n* Having had TMS done in the recent past (within a year)\n* Pregnancy assessed in female patients\n* Intracranial metallic objects (except for dental fillings)\n* Current use of substances or medications known to significantly reduce seizure threshold.",{"count":160,"type":22},[25],"This study's objective is to evaluate the effects of repetitive transcranial magnetic stimulation (rTMS) over the dorsolateral prefrontal cortex (dlPFC) of patients with Parkinson's Disease (PD) who experience impulse control disorders (ICDs) on impulse control symptoms and cognitive behaviors linked to ICDs: reinforcement learning and delay-discounting. This is a randomized sham-controlled cross-over trial. All patients will undergo a session of active rTMS and a session of sham rTMS, with the order of sessions randomized across participants. Following recruitment and eligibility screening, the eligible participants will undergo two sessions of rTMS (active and sham), immediately followed by neurocognitive tasks and questionnaires, no more than 1-2 weeks apart. Each session will have a duration of approximately 1-1.5 hours.",[230,231],"Impulse Control Disorder","Parkinson Disease","2026-04-16",{"date":190,"type":35},{"date":235,"type":35},"2024-05-01",{"date":237,"type":22},"2027-05",{"name":41,"class":42},{"id":240,"slug":241,"hasResults":12,"nctId":242,"briefTitle":243,"officialTitle":244,"acronym":4,"eligibilityCriteria":245,"healthyVolunteers":12,"sex":18,"minAge":246,"maxAge":247,"enrollmentInfo":248,"targetDuration":4,"studyType":23,"phases":249,"briefSummary":250,"conditions":251,"keywords":253,"overallStatus":142,"whyStopped":4,"lastUpdateSubmitDate":232,"lastUpdatePostDateStruct":261,"startDateStruct":262,"completionDateStruct":264,"leadSponsor":265,"locationsCount":43},"100406886","effects-of-blocking-blue-light-at-night-post-cabg-avr-mvr-cabg-avr-cabg-mvr-or-sah-100406886","NCT04578249","Effects of Blocking Blue Light at Night Post CABG, AVR, MVR, CABG AVR, CABG MVR, or SAH","Effects of Blocking Blue Light at Night on Patient Outcomes After Elective CABG, AVR, MVR, CABG AVR, CABG MVR, or SAH","Inclusion Criteria:\n\n* Both men and women that are undergoing elective (non-emergency)\n\n  * on-pump CABG surgery,\n  * AVR,\n  * MVR,\n  * CABG AVR,\n  * CABG MVR or\n  * SAH\n* No history of diagnosed psychiatric disorders or organ failure\n\nExclusion Criteria:\n\n* Evidence or diagnosis of dementia or other cognitive deficit\n* Diagnosed psychiatric disorder (including depression and anxiety)\n* Organ failure \\[kidney (creatine \\> 1.5 mg\u002FdL), liver, etc.\\]\n* Chronic obstructive pulmonary disease,\n* Any immune disorder\n* Acute infection\n* Prior cardiac surgery\n* Elective aneurysms\n* Combined cardiac operations\n* Left main stenosis greater than 70%\n* Left ventricular ejection fraction (LVEF) lower than 0.5\n* Any condition that increases likelihood of the need for a blood transfusion during or after the surgery\n* Clotting disorder\n* Suspected less than 8th grade English reading comprehension level","45 Years","75 Years",{"count":52,"type":22},[25],"Purpose The purpose of this study is to determine whether filtering out blue light at nighttime reduces post-surgical inflammation and\u002For moderates cognitive decline and mood and sleep alterations in patients undergoing elective CABG, AVR, MVR, CABG AVR, CABG MVR, or SAH surgery. If manipulating nighttime light in hospital rooms improves patient outcomes, then it would be a relatively easy and inexpensive innovation that could reduce post-surgical complications and save millions of dollars per year in health care costs by shortening the length of hospital stays and reducing morbidity. The investigators aim to determine the relationship between inflammation and cognitive dysfunction after cardiac surgery.",[252],"Circadian Rhythm Disorders",[254,255,256,257,258,259,260],"CABG","coronary artery bypass graft","light at night","dim light at night","inflammation","cognition","blue light",{"date":190,"type":35},{"date":263,"type":35},"2021-09-20",{"date":237,"type":22},{"name":41,"class":42},{"id":267,"slug":268,"hasResults":12,"nctId":269,"briefTitle":270,"officialTitle":271,"acronym":4,"eligibilityCriteria":272,"healthyVolunteers":158,"sex":18,"minAge":273,"maxAge":274,"enrollmentInfo":275,"targetDuration":4,"studyType":23,"phases":277,"briefSummary":278,"conditions":279,"keywords":4,"overallStatus":142,"whyStopped":4,"lastUpdateSubmitDate":282,"lastUpdatePostDateStruct":283,"startDateStruct":285,"completionDateStruct":287,"leadSponsor":288,"locationsCount":43},"100578223","nimh-clinical-pathway-in-rural-appalachian-school-based-health-clinics-100578223","NCT06808503","NIMH Clinical Pathway in Rural Appalachian School-based Health Clinics","Implementing the NIMH Clinical Pathway in Rural Appalachian School-based Health Clinics","Inclusion Criteria:\n\n* Youth who are receiving services at the school-based health centers to participate\n* Parents must be able to give legal consent for themselves and their children to participate\n* Youth and Parent must be English-speaking\n* Youth must also be able to give signed assent to participate\n* Youth must be cognitively and medically able to participate in study activities\n\nExclusion Criteria:\n\n* Youth in state custody will be excluded from study participation due to challenges related to obtaining legal consent.","12 Years","17 Years",{"count":276,"type":22},30,[25],"This study will adapt and evaluate an evidence-based suicide risk screening and follow-up program in two school-based health centers in West Virginia. The suicide screening program is titled the \"NIMH Clinical Pathway\" and provides tools and procedures for routinely screening adolescents for suicide risk, completing risk assessments, safety planning, lethal means restriction, follow-up referrals, and other disposition planning as appropriate.\n\nInvestigators aim to do the following:\n\n1. Gather formative data from providers, parents, and youth to inform ways to adapt and implement the NIMH Clinical Pathway so that it can be effectively implemented in rural, Appalachian School-Based Health Centers (SBHCs).\n2. Gather preliminary data regarding the feasibility, acceptability, and effectiveness of the adapted intervention.",[280,281],"Suicide Prevention","Suicide","2026-04-15",{"date":284,"type":35},"2026-04-21",{"date":286,"type":35},"2024-10-02",{"date":237,"type":22},{"name":41,"class":42},{"id":290,"slug":291,"hasResults":12,"nctId":292,"briefTitle":293,"officialTitle":294,"acronym":4,"eligibilityCriteria":295,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":296,"targetDuration":4,"studyType":23,"phases":298,"briefSummary":300,"conditions":301,"keywords":4,"overallStatus":142,"whyStopped":4,"lastUpdateSubmitDate":303,"lastUpdatePostDateStruct":304,"startDateStruct":305,"completionDateStruct":307,"leadSponsor":309,"locationsCount":43},"100472296","early-phase-1-safety-and-feasibility-of-hipec-for-high-risk-gallbladder-adenocarcinoma-100472296","NCT05430035","Safety and Feasibility of HIPEC for High-Risk Gallbladder Adenocarcinoma","Safety and Feasibility of Prophylactic Heated Intra-peritoneal Chemotherapy (HIPEC) for High-Risk Gallbladder Adenocarcinoma","Inclusion Criteria:\n\n* Subjects must have histologically or cytologically confirmed gallbladder adenocarcinoma AND inadvertent spillage of bile or intentional decompression during cholecystectomy OR tumors extending through the serosa of the gallbladder (T3\u002FT4) OR poorly differentiated gallbladder adenocarcinoma.\n* ECOG Performance status ≤ 2\n* Subjects must have normal organ and marrow function as defined below:\n\n  * Hemoglobin ≥ 10.0 g\u002Fdl\n  * Leukocytes ≥ 3,000\u002FmcL\n  * Absolute neutrophil count ≥ 1,500\u002FmcL\n  * Platelet count ≥ 100,000\u002FmcL\n  * Total bilirubin within normal institutional limits\n  * AST (SGOT) ≤ 2.5 X institutional upper limit of normal\n  * ALT (SGPT) ≤ 2.5 X institutional upper limit of normal\n  * Serum Creatinine within normal institutional limits\n* Eligible TNM staging includes \\>T1b meeting above criteria, any N, and M0\n* Eligible candidates for standard surgical management which includes central liver resection (+ cholecystectomy if not already performed) and portal lymphadenectomy\n* Subjects must have the ability to understand and the willingness to sign a written informed consent document\n\nExclusion Criteria:\n\n* Prior systemic therapy for gallbladder adenocarcinoma\n* Subjects receiving any other investigational agents.\n* Subjects with known or suspected metastatic disease\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to MMC or other agents used in this study.\n* Subjects with uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements.\n* Pregnant or breastfeeding are excluded from this study because MMC has the potential for teratogenic or abortifacient effects. Because there is known risk for adverse events in nursing infants secondary to treatment of the mother with MMC, breastfeeding should be discontinued if the mother is treated with MMC.\n* Subjects with past medical history of hepatitis B or C\n* Subjects with evidence of biliary obstruction thought to be cancer related, including subjects requiring biliary stent",{"count":297,"type":22},10,[299],"EARLY_PHASE1","Gallbladder adenocarcinoma is a devastating disease associated with a poor prognosis. Gallbladder and other biliary cancers will be responsible for an estimated 11,980 new cases, and 4,090 deaths in the US during 2020. The 5-year survival for all patients with gallbladder cancer is 18%, however this plummets to 2% for patients with metastatic disease. Patients with gallbladder cancer frequently develop peritoneal recurrence, particularly after intra-operative bile spillage during cholecystectomy for incidentally discovered gallbladder malignancy. Once developed, peritoneal metastases are difficult to treat and result in significant morbidity and mortality. As a result, novel approaches that target peritoneal metastases are needed for this disease. Prophylactic use of heated intraperitoneal chemotherapy (HIPEC) has been explored or is under active investigation for numerous gastrointestinal malignancies, including colon, gastric, and appendiceal cancers. HIPEC has efficacy in gallbladder cancer patients with macroscopic peritoneal disease undergoing cytoreductive surgery (CRS)\u002FHIPEC and has been associated with a survival advantage in a multi-institutional retrospective case series. Incidentally discovered gallbladder cancer is treated with central hepatectomy and portal lymphadenectomy, therefore a prophylactic HIPEC can be easily incorporated into the second operation performed as part of the standard of care. In this early phase clinical trial, the investigators will explore the safety and feasibility of prophylactic HIPEC for gallbladder cancer in patients at high-risk of peritoneal recurrence. The primary endpoint is to assess feasibility of the prophylactic heated intraperitoneal chemotherapy (HIPEC) approach in gallbladder cancer. The primary endpoints include occurrence of intra-operative complications, technical challenges, 90-day postoperative morbidity and mortality, length of stay and readmission, which will be documented and compared with historical controls after follow-up.",[302],"Gallbladder Adenocarcinoma","2026-04-14",{"date":190,"type":35},{"date":306,"type":35},"2022-06-23",{"date":308,"type":22},"2029-07",{"name":41,"class":42},{"id":311,"slug":312,"hasResults":12,"nctId":313,"briefTitle":314,"officialTitle":315,"acronym":4,"eligibilityCriteria":316,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":317,"targetDuration":4,"studyType":23,"phases":319,"briefSummary":320,"conditions":321,"keywords":4,"overallStatus":142,"whyStopped":4,"lastUpdateSubmitDate":303,"lastUpdatePostDateStruct":323,"startDateStruct":324,"completionDateStruct":326,"leadSponsor":328,"locationsCount":43},"100432492","phase-1-neoadjuvant-mfolfirinox-with-perioperative-oral-hydroxychloroquine-in-resectable-pancreatic-adenocarcinoma-100432492","NCT04911816","Neoadjuvant mFOLFIRINOX With Perioperative Oral Hydroxychloroquine in Resectable Pancreatic Adenocarcinoma","Phase I\u002FII Study of Neoadjuvant mFOLFIRINOX in Combination With Peri-operative Oral Hydroxychloroquine (FHQ) in Subjects With Resectable Adenocarcinoma of the Pancreas.","Inclusion Criteria\n\n* Subjects with biopsy-proven adenocarcinoma of the pancreas\n* Pancreatic protocol helical CT scan demonstrating absence of venous or arterial involvement, consistent with NCCN guidelines for resectable disease\n* ECOG performance status ≤ 1\n* No active second malignancy except for basal cell carcinoma of the skin\n* Normal renal, hepatic, and hematologic function at the time of enrollment as evidenced by:\n\n  * Serum creatinine level ≤1.5 the upper limits of normal\n  * Serum total bilirubin level ≤1.5 X ULN\n* White blood cell count ≥ 3.5x109\u002Fml per ml and platelet count ≥ 100x109 per ml\n* For subjects with obstructive jaundice, the biliary tract must be drained with a temporary plastic or a short permanent metallic biliary stent\n* Ability to understand and the willingness to sign a written informed consent document.\n\nExclusion Criteria\n\n* Subjects deemed surgically unresectable or subjects unwilling to undergo surgical resection.\n* Subjects who have received chemotherapy within 12 months prior to study entry.\n* Subjects who are found to have loss-of-function mutations in DPYD or UGTA1 by Oneome pharmacogenomic testing, resulting in increased risk of mFOLFIRINOX toxicity. DPYD mutations have been noted in 5% of the overall population. Homozygous UGT1A1 mutations have been noted in 10% of North Americans.\n* Prior use of radiotherapy or investigational agents for pancreatic cancer.\n* Any evidence of metastasis to distant organs (liver, lung, peritoneum).\n* Cross sectional imaging suggesting portal vein, superior mesenteric artery, hepatic artery involvement that would make the patient borderline resectable or locally advanced\n* Symptomatic or endoscopic evidence of gastric outlet obstruction.\n* Concurrent malignancies with evidence of active or measurable disease except basal cell carcinoma of the skin.\n* Inability to adhere to study and\u002For follow-up procedures.\n* History of allergic reactions or hypersensitivity to the study drugs (chloroquine, hydroxychloroquine, 5-Fluorouracil, Leucovorin, Oxaliplatin, Irinotecan).\n* Other concurrent experimental therapy.\n* The effects of HCQ, and mFOLFIRINOX on the developing human fetus are unknown. For this reason women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. All females of childbearing potential must have a blood test or urine study within two weeks prior to registration to rule out pregnancy. Should a woman become pregnant while participating in this study, she should inform her treating physician immediately. If a man impregnates a woman while participating in this study, he should inform his treating physician immediately as well.\n* Because patients with immune deficiency are at increased risk of lethal infections when treated with bone marrow-suppressive therapy, HIV-positive patients are excluded from the study. For patients receiving combination anti-retroviral therapy, the potential impact of pharmacokinetic interactions with HCQ and mFOLFIRINOX is unknown. Appropriate studies may be undertaken in patients with HIV and those receiving combination anti-retroviral therapy in the future.\n* Due to the risk of disease exacerbation, patients with porphyria are ineligible.\n* Patients with psoriasis are ineligible unless the disease is well controlled and they are under the care of a specialist who agrees to monitor the patient for exacerbations.\n* Patients requiring the use of enzyme-inducing anti-epileptic medication that includes: phenytoin, carbamazepine, phenobarbital, primidone or oxcarbazepine are excluded.\n* Patients with previously documented macular degeneration or diabetic retinopathy are excluded.\n* Baseline EKG with QTc \\>470 msec (including subjects on medication). Subjects with ventricular pacemaker for whom QT interval is not measurable will be eligible on a case-by-case basis.",{"count":318,"type":22},40,[162,163],"This will be a phase I\u002FII trial examining the safety and tolerability of pre-operative mFOLFIRINOX in combination with peri-operative oral hydroxychloroquine (FHQ) in the treatment of subjects with adenocarcinoma of the pancreas. Subjects will be staged prior to protocol entry by contrast-enhanced helical abdominal CT scan done using a pancreas mass protocol or EUS. Eligible subjects with biopsy-proven, resectable pancreatic adenocarcinoma without evidence of venous or arterial involvement on CT scan receive HCQ orally in combination with mFOLFIRINOX prior to surgery. Hydroxychloroquine will begin with the first dose of mFOLFIRINOX and continue for 2 weeks post-operatively. Three to six weeks after the last dose of mFOLFIRINOX, patients will undergo surgical exploration and pancreatectomy if technically feasible and all toxicities have resolved. Pathologic specimens will undergo detailed histopathologic and immunohistochemical evaluations with particular attention to the six surgical margins of resection: the bile duct margin (for Whipple specimens), the margin of pancreatic transection, the retroperitoneal margin, the proximal and distal duodenal margins (for Whipple specimens), and the portal vein margin along the pancreatic head (for Whipple specimens) or medial pancreas (for distal pancreatectomies). Tissue specimens will be stored at -80C for future correlative studies of autophagy and tumor response to protocol therapy. Ten to fourteen weeks following completion of successful surgical removal of their tumor, subjects will undergo repeat staging studies per standard of care. Subjects will pursue standard of care adjuvant therapy options at the discretion of their physician.",[322],"Adenocarcinoma of the Pancreas",{"date":190,"type":35},{"date":325,"type":35},"2021-07-16",{"date":327,"type":22},"2030-06",{"name":41,"class":42},{"id":330,"slug":331,"hasResults":12,"nctId":332,"briefTitle":333,"officialTitle":334,"acronym":4,"eligibilityCriteria":335,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":336,"targetDuration":4,"studyType":23,"phases":338,"briefSummary":339,"conditions":340,"keywords":4,"overallStatus":142,"whyStopped":4,"lastUpdateSubmitDate":343,"lastUpdatePostDateStruct":344,"startDateStruct":345,"completionDateStruct":347,"leadSponsor":349,"locationsCount":43},"100480585","phase-2-prospective-evaluation-of-xerava-prophylaxis-in-hematological-malignancy-patients-with-prolonged-neutropenia-100480585","NCT05537896","Prospective Evaluation of Xerava Prophylaxis in Hematological Malignancy Patients With Prolonged Neutropenia","Prospective Evaluation of Xerava™ (Eravacycline) Prophylaxis in Hematological Malignancy Patients With Prolonged Neutropenia","Inclusion Criteria:\n\n* All patients receiving induction chemotherapy for treatment of acute leukemia or receiving preparative regimen for HSCT\n* Patient must provide informed consent.\n* Bilirubin ≤ 3 x the ULN and AST\u002FALT ≤ 5 x ULN\n\nExclusion Criteria:\n\n* Uncontrolled bacterial, viral or fungal infection at the time of study enrollment.\n* Urinary tract infection receiving active treatment\n* Acute pancreatitis (not necessary to work-up unless symptomatic)\n* History of known hypersensitivity to eravacycline, tetracycline, doxycycline, minocycline, tigecycline, sarecycline, oxytetracycline, or omadacycline\n* Pseudomonas infection within 30 days prior to study enrollment\n* Receiving strong inhibitors or inducers of cytochrome P450 3A4 will be excluded from the study (see Appendix B for complete list of medications)\n* Pregnant or lactating women",{"count":337,"type":22},55,[163],"Antibacterial prophylaxis is recommended in patients at high risk of infection, specifically patients undergoing acute leukemia induction therapy or hematopoietic stem cell transplant (HSCT) who are expected to have profound neutropenia (ANC\\\u003C100 neutrophils\u002Fmilliliter) for more than seven days. Xerava™ (eravacycline) has a broad spectrum of activity including many multi-drug resistant strains of bacteria. It is not an agent used for treatment of febrile neutropenia, making eravacycline a very attractive alternative to consider in this prophylactic setting. Eravacycline has activity against MRSA, VRE, and Clostridioides difficile, all of which are common problems in this patient population. It also covers the majority of enteric gram-negative pathogens while also producing satisfactory tissue penetration and adequate plasma concentrations, which has classically been a concern with prior agents. Eravacycline has activity against coagulase-negative staphylococcus, which is a common catheter-related infection in leukemia and HSCT patients. The primary objective will be report the incidence of breakthrough infections during eravacycline prophylaxis for hematologic malignancy patients with prolonged neutropenia.",[341,342],"Hematological Malignancy","Neutropenia","2026-04-12",{"date":232,"type":35},{"date":346,"type":35},"2024-02-19",{"date":348,"type":22},"2028-02",{"name":41,"class":42},{"id":351,"slug":352,"hasResults":12,"nctId":353,"briefTitle":354,"officialTitle":355,"acronym":4,"eligibilityCriteria":356,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":357,"targetDuration":4,"studyType":23,"phases":358,"briefSummary":359,"conditions":360,"keywords":364,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":366,"lastUpdatePostDateStruct":367,"startDateStruct":368,"completionDateStruct":370,"leadSponsor":372,"locationsCount":4},"100583414","impact-of-tai-chi-in-cervical-myelopathy-100583414","NCT06876012","Impact of Tai Chi in Cervical Myelopathy","Impact of Tai Chi on Balance and Fall Risk in Patients With Cervical Myelopathy","Inclusion Criteria:\n\n* Diagnosis of Cervical Myelopathy with planned surgery\n* 18 years of age or older\n* Able to participate in intervention (attend and participate in classes)\n\nExclusion Criteria:\n\n* Wheelchair bound at initial visit\n* Other verified potential cause of gait instability\u002Fbalance problems\n* Unable to participate in intervention (unable to attend\u002Fparticipate in classes)",{"count":160,"type":22},[25],"The goal of this observational study is to determine if patients with cervical myelopathy who participate in a Tai Chi program will demonstrate improved gait and balance compared to patients who undergo usual care.\n\nParticipants must be 18 years or older and have a diagnosis of cervical myelopathy.",[361,362,363],"Cervical Myelopathy","Balance Assessment","Fall Risk",[365],"Surgery","2026-04-10",{"date":282,"type":35},{"date":369,"type":22},"2026-12",{"date":371,"type":22},"2028-07",{"name":41,"class":42},{"id":374,"slug":375,"hasResults":12,"nctId":376,"briefTitle":377,"officialTitle":378,"acronym":4,"eligibilityCriteria":379,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":380,"targetDuration":4,"studyType":23,"phases":382,"briefSummary":383,"conditions":384,"keywords":4,"overallStatus":142,"whyStopped":4,"lastUpdateSubmitDate":387,"lastUpdatePostDateStruct":388,"startDateStruct":390,"completionDateStruct":392,"leadSponsor":394,"locationsCount":43},"100610053","phase-2-subcutaneous-blinatumomab-for-treatment-of-adult-patients-with-cd19-positive-mixed-phenotype-acute-leukemia-mpal-100610053","NCT07222579","Subcutaneous Blinatumomab for Treatment of Adult Patients With CD19-Positive Mixed Phenotype Acute Leukemia (MPAL)","A Multicenter Phase II Study of Subcutaneous Blinatumomab for Treatment of Adult Patients With CD19-Positive Mixed Phenotype Acute Leukemia (MPAL)","* Inclusion Criteria:\n* General Criteria for all three Cohorts\n\n  * Subjects must have histologically or cytologically confirmed MPAL based on 2022 WHO criteria\n  * Subjects who have undergone allo-HSCT are eligible if they are ≥ 4 weeks post stem cell infusion, have no evidence of GVHD \\> Grade 2, and are at least ≥ 1 week off of immunosuppressive therapy. Per FDA recommendation, patients should be off of calcineurin inhibitors (CNIs) for at least 4 weeks before receiving blinatumomab\n  * Subjects with a CNS leukemia must be clinically stable (i.e., asymptomatic with no focal neurological signs and symptoms, or signs and symptoms unchanged over 4 weeks with no \\> grade 2 manifestations) with a flow cytometric clear CSF in the 2 weeks prior to day 1 of SC-blinatumomab administration.\n  * Ability to understand and willingness to sign a written informed consent document\n  * Agree to comply with the study requirements and agree to come to the clinic\u002Fhospital for required study visits\n  * Subjects with hematologic malignancies are expected to have hematologic abnormalities at study entry\n* Specific Criteria for Cohort A\n\n  o Subjects should be ineligible for available induction therapy either if they are 75 years of age or older or if they have at least one of the following coexisting conditions precluding intensive chemotherapy: a history of CHF for which treatment is warranted or a report of EF ≤50% in the last 12 months, a history of chronic stable angina, a report of DLCO of ≤65% or FEV1 ≤65% in the last 12 months, ECOG performance status 3 or 4, Charlson comorbidity index (CCI) ≥3.\n* Specific Criteria for Cohort B\n\n  * CD19+ MPAL in CR\u002FCRh\u002FCRi after at least one line of treatment with MRD positivity at a level of ≥0.1% using an assay with a minimum sensitivity of 0.01%.\n  * ECOG performance status ≤2\n  * Subjects must have organ function as below:\n\n    * Direct bilirubin ≤ 2.5 mg\u002FdL\n    * AST\u002FALT\u002FAlkaline phosphatase ≤ 5 X institutional upper limit of normal\n    * Serum creatinine ≤ 3 mg\u002FdL\n* Specific Criteria for Cohort C\n\n  * Confirmed R\u002FR CD19+ MPAL\n  * Previous cytotoxic chemotherapy (except for hydroxyurea) must have been completed by 5 half-lives of the drug(s) prior to day 1 of SC-blinatumomab. Per FDA recommendation, patients should have recovered to no more than Grade 1 toxicities from prior chemotherapy.\n  * ECOG performance status ≤2\n  * Subjects must have organ function as below:\n\n    * Direct bilirubin ≤ 2.5 mg\u002FdL\n    * AST\u002FALT\u002FAlkaline phosphatase ≤ 5 X institutional upper limit of normal\n    * Serum creatinine ≤ 3 mg\u002FdL\n* Exclusion Criteria:\n* Criteria for all three Cohorts\n\n  * Subjects receiving any other investigational agents, or concurrent chemotherapy, radiation therapy, or immunotherapy for cancer treatment not including corticosteroids or hydroxyurea\n  * Active, uncontrolled infection; subjects with infection under active treatment and controlled with antimicrobials are eligible",{"count":381,"type":22},78,[163],"This is a multicenter, non-randomized, open-label, phase II study evaluating blinatumomab administered subcutaneously in adult subjects with CD19+ MPAL. This trial consists of three cohorts of patients with CD19-positive MPAL, categorized as follows: 1. Cohort A: Newly diagnosed CD19+ MPAL in untreated patients who are either ≥ 75 years of age or have at least one coexisting condition precluding intensive chemotherapy. 2. Cohort B: Patients with CD19+ MPAL who have achieved complete remission (CR, CRh, or CRi) following at least one line of treatment but have detectable measurable residual disease (MRD) at a level of ≥ 0.1%, assessed using an assay with a minimum sensitivity of 0.01%. 3. Cohort C: Patients with CD19+ MPAL with morphologic relapsed or refractory (R\u002FR) disease following at least one prior line of treatment. The Primary Objectives for each cohort are for Cohort A: to evaluate the efficacy of SC-blinatumomab in treatment; for Cohort B: to assess the ability of SC-blinatumomab to achieve MRD-negative CR; for Cohort C: to determine the efficacy of SC-blinatumomab in inducing CR, CRh, or CRi in patients.\n\nAt specified time points, subjects will undergo the following procedures: collection of informed consent, medical history, demographics, ECOG performance, and physical exam including vital signs as well as neurological examination including examination of writing ability. Subjects will provide samples for complete blood count with differential and blood chemistry profile, have a bone marrow aspiration and biopsy and lumbar puncture will be performed per protocol or if clinically indicated, and\u002For ECG, Echocardiography, pulmonary function test will be performed only if medically indicated.\n\nThe subcutaneous treatment will be given in both the inpatient and outpatient setting. For an individual subject the length of participation includes up to a 3-week screening period, up to a 13-month treatment period, and a safety follow-up visit (30 days after the last dose of study treatment), and a follow-up period.",[385,386],"CD19 Positive","Mixed Phenotype Acute Leukemia (MPAL)","2026-04-08",{"date":389,"type":35},"2026-04-13",{"date":391,"type":35},"2026-01-15",{"date":393,"type":22},"2031-08",{"name":41,"class":42},{"id":396,"slug":397,"hasResults":12,"nctId":398,"briefTitle":399,"officialTitle":400,"acronym":4,"eligibilityCriteria":401,"healthyVolunteers":12,"sex":18,"minAge":246,"maxAge":402,"enrollmentInfo":403,"targetDuration":4,"studyType":23,"phases":405,"briefSummary":406,"conditions":407,"keywords":410,"overallStatus":142,"whyStopped":4,"lastUpdateSubmitDate":415,"lastUpdatePostDateStruct":416,"startDateStruct":418,"completionDateStruct":420,"leadSponsor":422,"locationsCount":43},"100576942","sustaining-home-heart-failure-palliative-care-in-rural-appalachia-100576942","NCT06791850","Sustaining Home Heart Failure Palliative Care in Rural Appalachia","Sustaining Home Palliative Care for Patients With Heart Failure (HF) and Their Family Caregivers in Rural Appalachia: A Mixed Methods Randomized Clinical Trial (RCT).","Inclusion Criteria:\n\n1. Adult patients' age between 50 to 80 years with advanced HF (NYHA III or IV), diagnosed by physician\n2. Caregivers' age between 45 to 80 years.\n3. Alert and consent to participate\n4. Able to read and understand English\n\nExclusion Criteria:\n\n1. Already received or are on a waiting list for a heart transplant or left ventricular assist device (LVAD)\n2. Diagnosed with a terminal illness or dementia, such as Alzheimer's disease","80 Years",{"count":404,"type":22},208,[25],"The aim of this mixed methods randomized controlled trial is to test the integrated nurse-led intervention bundle for family home care management of end-stage heart failure and palliative care in rural Appalachia. This intervention bundle is designed to address rural disparities in access to health care, with the help of the faith-based nurses and local volunteer visiting neighbors.",[408,409],"Heart Failure NYHA Class III","Heart Failure NYHA Class IV",[411,412,413,414],"advanced heart failure","home palliative care","family caregiver","rural Appalachia","2026-03-05",{"date":417,"type":35},"2026-03-09",{"date":419,"type":35},"2025-04-01",{"date":421,"type":22},"2028-05-31",{"name":41,"class":42},{"id":424,"slug":425,"hasResults":12,"nctId":426,"briefTitle":427,"officialTitle":427,"acronym":4,"eligibilityCriteria":428,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":429,"enrollmentInfo":430,"targetDuration":4,"studyType":23,"phases":432,"briefSummary":433,"conditions":434,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":436,"lastUpdatePostDateStruct":437,"startDateStruct":439,"completionDateStruct":441,"leadSponsor":443,"locationsCount":43},"100622597","xpan-non-inferiority-study-100622597","NCT07385690","Xpan Non-Inferiority Study","Inclusion Criteria:\n\n* Individuals scheduled for the following procedures:\n\n  * Sleeve Gastrectomy\n  * Bypass\n  * Revision \\& other bariatric procedures\n  * Robotic procedures\n  * Bariatric patients\n\nExclusion Criteria:\n\n* Any individual not scheduled for the above procedure and\u002For does not meet the age requirments.","89 Years",{"count":431,"type":22},35,[25],"A trocar is a surgical instrument with a sharp point and tube and is used to create endoscopic access in the abdomen or chest where endoscopic instruments can be entered \\& used in minimally invasive surgical procedures. Xpan has created an FDA Cleared radially dilating trocar (RDT) that is inserted at 3mm and can be expanded to 5mm or 12mm during surgery. The purpose of this research protocol is to demonstrate that a new FDA Cleared Xpan® radially dilating trocar (RDT) system is at least, just as effective as the existing RDT trocar systems. The procedure will be performed using a radially dilating trocar that is inserted at 3mm and can be expanded to 5mm or 12mm during surgery.",[435],"Bariatric Surgery Candidate","2026-02-02",{"date":438,"type":35},"2026-02-04",{"date":440,"type":22},"2026-02",{"date":442,"type":22},"2027-02",{"name":41,"class":42},{"id":445,"slug":446,"hasResults":12,"nctId":447,"briefTitle":448,"officialTitle":449,"acronym":4,"eligibilityCriteria":450,"healthyVolunteers":158,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":451,"targetDuration":4,"studyType":134,"phases":4,"briefSummary":453,"conditions":454,"keywords":459,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":391,"lastUpdatePostDateStruct":462,"startDateStruct":464,"completionDateStruct":466,"leadSponsor":468,"locationsCount":43},"100617366","rapid-hiv-hep-c-and-syphilis-screening-in-a-rural-street-medicine-clinic-100617366","NCT07317687","Rapid HIV, Hep C, and Syphilis Screening in a Rural Street Medicine Clinic","Rapid HIV, Hepatitis C, and Syphilis Screening in a Rural Street Medicine Clinic in West Virginia","Inclusion Criteria:\n\n* Patients of the WVU Medicine Street Medicine team\n\nExclusion Criteria:\n\n* Patients under the age of 18",{"count":452,"type":22},200,"West Virginia faces rising rates of HIV, hepatitis, and syphilis, particularly among individuals experiencing homelessness, substance use, and mental health challenges. Traditional blood-draw testing for these infections is often hindered by mistrust, logistical barriers, and delays in results. This study, conducted by the West Virginia University (WVU) Street Medicine program, evaluates a rapid, point-of-care fingerstick test for HIV, Hepatitis C, and syphilis that provides results within 10-20 minutes during mobile clinic visits. Participants may choose rapid testing, traditional blood draw (which also includes Hepatitis B screening), or decline testing. All participants will be invited to complete a brief survey about the experiences with screening methods. The goal is to assess whether rapid testing improves screening uptake, linkage to care, and patient satisfaction, ultimately reducing barriers and disease burden in high-risk populations.",[455,456,457,458],"HIV Testing","HEPATITIS C (HCV)","Syphilis","Hepatitis B Virus (HBV)",[460,461],"Street Medicine","Rapid Fingerstick Testing",{"date":463,"type":35},"2026-01-20",{"date":465,"type":22},"2026-01",{"date":467,"type":22},"2028-01",{"name":41,"class":42},{"id":470,"slug":471,"hasResults":12,"nctId":472,"briefTitle":473,"officialTitle":474,"acronym":4,"eligibilityCriteria":475,"healthyVolunteers":12,"sex":476,"minAge":19,"maxAge":4,"enrollmentInfo":477,"targetDuration":4,"studyType":23,"phases":479,"briefSummary":480,"conditions":481,"keywords":484,"overallStatus":142,"whyStopped":4,"lastUpdateSubmitDate":488,"lastUpdatePostDateStruct":489,"startDateStruct":491,"completionDateStruct":493,"leadSponsor":494,"locationsCount":43},"100589923","lifting-more-than-weights-resistance-exercise-program-across-socioeconomic-groups-for-cancer-related-fatigue-management-100589923","NCT06960720","Lifting More Than Weights: Resistance Exercise Program Across Socioeconomic Groups for Cancer-Related Fatigue Management","Lifting More Than Weights: Feasibility of Implementing a Resistance Exercise Program Across Socioeconomic Groups for Cancer-Related Fatigue Management","Inclusion Criteria:\n\n* Subjects must have histologically or cytologically confirmed Breast Cancer; any tumor molecular subtype can be enrolled.\n* Subjects must have been diagnosed with non-metastatic breast cancer, defined as stage 0, I, II, or III (according to the American Joint Committee on Cancer Tumor, Node, Metastasis staging system), and must be between one and three years post-diagnosis at the time of enrollment. With treatment being received from the West Virginia University (WVU) Cancer Institute.\n* Any severity or report of fatigue. This can be done through a subjective report documented by any healthcare professional or through a screening tool like the enhanced distress thermometer.\n* Subjects must have the ability to understand and the willingness to sign a written informed consent document.\n* Subjects who are pregnant (first or second trimester) or breastfeeding must receive additional approval from their obstetrics and gynecology physician for participation. Only individuals with a singleton pregnancy (no multiple gestations) will be eligible for participation. Pregnant participants must be in their first or second trimester at the time of enrollment to ensure they can complete the full three-month program before childbirth. Multiple gestations are associated with higher risks of pregnancy complications, increased physical limitations, and a greater likelihood of preterm delivery, which may prevent completion of the program.\n\nExclusion Criteria:\n\n* Male biological gender. Males will be excluded from the study due to the rarity of male breast cancer and the variability gender creates on AL scores.\n* Subjects with uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, unstable angina pectoris, cardiac arrhythmia, active alcoholism, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements.\n* Subjects with pregnancy beyond the second trimester at the time of enrollment, as later stages of pregnancy may prevent completion of the full three-month program.\n* Subjects who are pregnant with multiple gestations (e.g., twins, triplets, or higher-order pregnancies) due to the increased risk of pregnancy-related complications, physical limitations, and the likelihood of preterm delivery, which may interfere with program completion.\n* Subjects whose self-reported household income is above or below the median household income in Appalachia ($61,688) and for whom the target enrollment of 30 participants in that respective SES group (higher or lower) has already been met at the time of screening, as representation of both SES groups is required for the study.","FEMALE",{"count":478,"type":22},60,[25],"The long-term goal of this project is to improve the implementation of tailored resistance exercise interventions for Appalachian breast cancer survivors. To achieve this goal, the primary objective is to enhance the understanding of how biological, psychological, and social factors interact to influence readiness for behavior change around resistance exercise in this unique population. The primary aim is to evaluate the feasibility of delivering the Strength After Breast Cancer (SABC) program, focusing on how socioeconomic status (SES) and allostatic load (AL) scores influence adherence and dropout rates. The Investigators will also further examine how self-efficacy, outcome expectations, and social support influence behavior change related to resistance exercise participation. The central hypothesis is that participants with lower SES will report geographic or financial constraints, receive reduced support from family or peers, have low confidence in their ability to exercise, and demonstrate lower adherence rates.\n\nParticipants will:\n\n* Use a clear, step-by-step guide for safe, progressive strength training using a resistance exercise program tailored specifically for breast cancer survivors for a duration of 3 months\n* Keep an exercise log and complete questionnaires",[482,483],"Breast Cancer","Fatigue",[485,486,487],"Strength After Breast Cancer","Allostatic load","Cancer Related Fatigue","2025-10-29",{"date":490,"type":35},"2025-10-31",{"date":492,"type":35},"2025-10-13",{"date":217,"type":22},{"name":41,"class":42},{"id":496,"slug":497,"hasResults":12,"nctId":498,"briefTitle":499,"officialTitle":499,"acronym":4,"eligibilityCriteria":500,"healthyVolunteers":158,"sex":18,"minAge":19,"maxAge":501,"enrollmentInfo":502,"targetDuration":4,"studyType":23,"phases":504,"briefSummary":505,"conditions":506,"keywords":4,"overallStatus":142,"whyStopped":4,"lastUpdateSubmitDate":488,"lastUpdatePostDateStruct":509,"startDateStruct":510,"completionDateStruct":512,"leadSponsor":514,"locationsCount":43},"100568875","phase-1-the-effects-of-cannabidiol-on-the-driving-performance-of-healthy-adults-by-dose-and-sex-100568875","NCT06686914","The Effects of Cannabidiol on the Driving Performance of Healthy Adults by Dose and Sex","Inclusion Criteria:\n\n* Possess a current drivers' license\n* Driven a motor vehicle at least once in the past 30 days\n* Able to read English\n* Test negative for all substances on a urine drug test and complete a test drive to ensure the absence of simulation sickness\n* Not taking any daily prescription medications (excluding birth control)\n* Not diagnosed with any serious chronic disease by a licensed healthcare provider (including but not limited to Alzheimer's and related dementias, Parkinson's disease or other neurodegenerative disorder, major depressive or anxiety disorder, schizophrenia or other serious mental illness, arrhythmias, cataracts, glaucoma, chronic obstructive pulmonary disease, diabetes, epilepsy, sleep apnea, and fibromyalgia)\n* Have an individual willing to drive them home after testing or be taken home by study staff after testing\n\nExclusion Criteria:\n\n* Currently smoke, vape or use tobacco products, used CBD in the past 30 days\n* Used illegal drugs in the past 30 days (e.g., cocaine\u002Fcrack, heroin, methamphetamine, 3,4-methylenedioxy-methamphetamine, inhalants, phencyclidine, lysergic acid diethylamide, psilocybin mushrooms, or marijuana)\n* Are pregnant or lactating at time of study","30 Years",{"count":503,"type":22},300,[162],"The objectives\u002Fpurpose of this study are to comprehensively investigate the effects of non-prescription CBD on driving performance, drowsiness, sedation, and cognitive function in a large sample of healthy adults aged 18-30 years, with additional characterization of effects by dose and by sex, using a rigorous RCT design which will naturally mitigate confounding factors.",[507,508],"Cannabidiol Effects","Driving Performance",{"date":490,"type":35},{"date":511,"type":35},"2025-06-30",{"date":513,"type":22},"2029-05-01",{"name":41,"class":42},{"id":516,"slug":517,"hasResults":12,"nctId":518,"briefTitle":519,"officialTitle":519,"acronym":4,"eligibilityCriteria":520,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":19,"enrollmentInfo":521,"targetDuration":4,"studyType":23,"phases":522,"briefSummary":524,"conditions":525,"keywords":527,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":530,"lastUpdatePostDateStruct":531,"startDateStruct":533,"completionDateStruct":535,"leadSponsor":537,"locationsCount":43},"100609141","phase-3-orthodontic-pain-alleviation-with-chewing-gum-100609141","NCT07210697","Orthodontic Pain Alleviation With Chewing Gum","Inclusion Criteria:\n\n* Participant and Parents able to sign and understand consent\n* Ability to chew gum\n\nExclusion Criteria:\n\n* Pregnant or Breastfeeding women",{"count":478,"type":22},[523],"PHASE3","The aim of this study is to determine whether chewing gum can alleviate orthodontic treatment discomfort and improve orthodontic treatment experience. The long-term goal is to enable clinicians to decide whether prescription of chewing gum at the placement of orthodontic appliances can improve patient experience with orthodontic treatment. In specific, a total of 60 patients under the age of 18 will be recruited for the study. Consent will be signed by both the child patient and the parents. 30 patients will be asked to chew xylitol gum and the other 30 patients will refrain from chewing gum and serve as the control group. At the appointment for insertion of orthodontic appliances, patients will be instructed to chew one serving or two pieces of xylitol gum three times per day for a total of six grams of xylitol per day. Patients will participate in a survey at the following timepoints- 4 hours, 24 hours, 48 hours and 7 days. The expectation is that this study will determine the effectiveness of using xylitol to decrease pain in orthodontic patients.",[526],"Orthodontic Appliances",[528,529],"Orthodontic Pain","xylitol gum","2025-09-29",{"date":532,"type":35},"2025-10-07",{"date":534,"type":22},"2025-10",{"date":536,"type":22},"2026-03",{"name":41,"class":42},{"id":539,"slug":540,"hasResults":12,"nctId":541,"briefTitle":542,"officialTitle":543,"acronym":4,"eligibilityCriteria":544,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":545,"enrollmentInfo":546,"targetDuration":4,"studyType":23,"phases":547,"briefSummary":548,"conditions":549,"keywords":552,"overallStatus":142,"whyStopped":4,"lastUpdateSubmitDate":555,"lastUpdatePostDateStruct":556,"startDateStruct":558,"completionDateStruct":560,"leadSponsor":562,"locationsCount":43},"100590020","remote-vinyasa-yoga-program-for-heart-health-100590020","NCT06961981","Remote Vinyasa Yoga Program for Heart Health","Feasibility, Acceptability, and Preliminary Efficacy of a Remote Vinyasa Yoga Program for Heart Health","Inclusion Criteria:\n\n* Individuals with a resting systolic BP \\>130 mmHg\n\nExclusion Criteria:\n\n* Report currently meeting aerobic activity guidelines (150 min\u002Fwk)\n* Practice yoga regularly (1 or more day\u002Fwk in the past month)\n* Have physical limitations or a major medical condition contraindicating yoga or assessments\n* Have uncontrolled HTN (systolic BP 160 mmHg or diastolic BP 100 mmHg)\n* Are currently pregnant or planning to become pregnant within 6 months\n* Are not on a stable dose of medications that could affect study outcomes\n* Are concurrently enrolled in another lifestyle program\n* No vulnerable populations will be included","65 Years",{"count":276,"type":22},[25],"The purpose of this study is to test a 12-week vinyasa yoga (flow yoga) intervention via Zoom. This program will be for 30 individuals with high blood pressure. 15 will receive the intervention and 15 will follow their usual routine. The investigators will determine if this vinyasa yoga program is feasible and acceptable in this population. Investigators will measure and compare blood pressure and other health responses such as physical health and well-being before and after participants complete the intervention or usual care period. The investigators hope to demonstrate that vinyasa yoga is a good option to improve heart health in people with high blood pressure.\n\nPrimary Objective - Examine the feasibility, acceptability, and preliminary efficacy of a 12-wk remotely-delivered vinyasa yoga intervention (3 x per week) on cardiovascular (CV) health in adults with hypertension (HTN).",[550,551],"Hypertension","Cardiovascular Diseases",[553,554],"Yoga","vinyasa yoga","2025-08-12",{"date":557,"type":35},"2025-08-17",{"date":559,"type":35},"2025-08-01",{"date":561,"type":22},"2026-05",{"name":41,"class":42},{"id":564,"slug":565,"hasResults":12,"nctId":566,"briefTitle":567,"officialTitle":567,"acronym":568,"eligibilityCriteria":569,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":570,"enrollmentInfo":571,"targetDuration":4,"studyType":23,"phases":572,"briefSummary":573,"conditions":574,"keywords":576,"overallStatus":142,"whyStopped":4,"lastUpdateSubmitDate":193,"lastUpdatePostDateStruct":579,"startDateStruct":581,"completionDateStruct":583,"leadSponsor":585,"locationsCount":43},"100493503","strengthening-tourette-treatment-options-using-tms-to-improve-cbit-a-double-blind-randomized-controlled-study-100493503","NCT05705999","Strengthening Tourette Treatment OPtions Using TMS to Improve CBIT, a Double-blind, Randomized, Controlled Study","STOP-TIC","Inclusion Criteria:\n\n* Age 18 years or older\n* Diagnosis of Tourette Syndrome\n* Moderate Tic Severity at baseline\n\nExclusion Criteria:\n\n* Presence of metallic objects or neurostimulators in the brain\n* Pregnancy\n* History of active seizures or epilepsy\n* Contraindications to receiving fMRI\n* Inability to participate in CBIT due to other underlying cognitive or medical condition","100 Years",{"count":160,"type":22},[25],"This pilot study will investigate the clinical and neurophysiological effects of repetitive transcranial magnetic stimulation (rTMS) followed by comprehensive behavioral intervention for tics (CBIT) in adult patients with Tourette's Syndrome (TS). Two groups of moderate disease severity will be randomized to receive active or sham rTMS targeted to the supplementary motor area (SMA) followed by eight CBIT sessions. The change in tic frequency and severity (primary outcome) and neurophysiological changes (secondary outcome) will be compared between the two groups. The central hypothesis is that low frequency rTMS will augment the effects of CBIT through favorable priming of the SMA network.",[575],"Tourette Syndrome",[575,577,578],"Comprehensive Behavioral Intervention for Tics","Transcranial Magnetic Stimulation",{"date":580,"type":35},"2025-07-18",{"date":582,"type":35},"2024-03-12",{"date":584,"type":22},"2026-12-30",{"name":41,"class":42},{"id":587,"slug":588,"hasResults":12,"nctId":589,"briefTitle":590,"officialTitle":590,"acronym":591,"eligibilityCriteria":592,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":593,"targetDuration":4,"studyType":23,"phases":595,"briefSummary":596,"conditions":597,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":599,"lastUpdatePostDateStruct":600,"startDateStruct":602,"completionDateStruct":604,"leadSponsor":606,"locationsCount":43},"100598402","preventing-perinatal-anxiety-testing-an-internet-delivered-intervention-100598402","NCT07071025","Preventing Perinatal Anxiety: Testing an Internet-delivered Intervention","P-POD","Inclusion Criteria:\n\n* Pregnant and entering second trimester\n* In a romantic relationship\n* Partner must be agreeable to participate\n* State Trait Anxiety Inventory-Trait Total ≥ 44 and\u002For Obsessive Beliefs Questionnaire-44 Total ≥ 139\n\nExclusion Criteria:\n\n-Must speak English",{"count":594,"type":22},100,[25],"Postpartum anxiety disorders are the most prevalent postpartum psychiatric conditions. The purpose of this study is to evaluate the Internet-delivered postpartum anxiety and obsessive-compulsive disorder (OCD) prevention program, called \"Preventing Postpartum Onset Distress\", or P-POD. The overarching goal of this study is to conduct a randomized control trial of P-POD, an online program designed to reduce and prevent perinatal anxiety in at-risk women in West Virginia. Investigators will test the effects of P-POD compared to an anxiety education control intervention on risk factors for perinatal anxiety and assess mothers' anxiety symptoms, relationships with their partners, and relationships with their infants at 8-weeks postpartum. Eligible women and their partners will be consented at the start of the second trimester of pregnancy. Couples will be randomized into either the P-POD (active) or ANX-ED (control) intervention. Couples will then begin to work through the ten intervention modules: seven modules for women, at a recommended rate of one per week, and three modules for partners, at a recommended rate of no more than one per week. Women will complete brief weekly phone \"coaching calls\" to encourage module completion, ensure understanding of material, and answer any content-related or technical questions. Ten weeks after the pre-intervention assessment, women will complete the post-intervention assessment (same measures as pre-assessment).",[598],"Postpartum Disorder","2025-07-08",{"date":601,"type":35},"2025-07-17",{"date":603,"type":22},"2025-08",{"date":605,"type":22},"2027-12",{"name":41,"class":42},""]